Hims & Hers Health (HIMS) Stock Forecast & Price Target

Compare

8,929 Followers

See the Price Targets and Ratings of:

All Analysts

Top Analysts

Premium

HIMS Analyst Ratings

Hold

3 Buy

6 Hold

3 Sell

Based on 12 analysts giving stock ratings to

Hims

& Hers Health

in the past 3 months

TipRanks enables you to focus on the analyst rating consensus of all analysts or only the top performers in the past 3 months

HIMS Stock 12 Month Forecast

Average Price Target

$32.95

▲(102.15% Upside)

Based on 12 Wall Street analysts offering 12 month price targets for Hims & Hers Health in the last 3 months. The average price target is $32.95 with a high forecast of $60.00 and a low forecast of $16.50. The average price target represents a 102.15% change from the last price of $16.30.

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"15":"$15","27":"$27","39":"$39","51":"$51","63":"$63"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":60,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$60.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":32.95,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$32.95</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":16.5,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$16.50</span>\n  </div></div>","useHTML":true}}],"tickPositions":[15,27,39,51,63],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"May<br/>2025","6":"Aug<br/>2025","9":"Nov<br/>2025","12":"Feb<br/>2026","25":"Feb<br/>2027"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.44,29.021538461538462,31.603076923076927,34.184615384615384,36.76615384615385,39.34769230769231,41.92923076923077,44.510769230769235,47.0923076923077,49.673846153846156,52.255384615384614,54.836923076923085,57.41846153846154,{"y":60,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.44,26.94076923076923,27.441538461538464,27.942307692307693,28.443076923076923,28.943846153846156,29.444615384615386,29.94538461538462,30.446153846153848,30.946923076923078,31.44769230769231,31.94846153846154,32.44923076923077,{"y":32.95,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,26.44,25.675384615384615,24.910769230769233,24.146153846153847,23.38153846153846,22.61692307692308,21.852307692307694,21.087692307692308,20.323076923076925,19.55846153846154,18.793846153846154,18.02923076923077,17.264615384615386,{"y":16.5,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":37.28,"date":1738368000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 21,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":45.09,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 15, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 12</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":31.05,"date":1743465600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 11,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":36.16,"date":1746057600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 8,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 25, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 16</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":56.77,"date":1748736000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 12,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 32, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 17</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":47.96,"date":1751328000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 19,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":62.55,"date":1754006400000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 17,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 31, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":41.53,"date":1756684800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Moderate Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 14,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 26, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 11</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":56.31,"date":1759276800000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 6,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 28, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":45.46,"date":1761955200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 5,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 35, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 18</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":37.51,"date":1764547200000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 38, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 15</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":32.47,"date":1767225600000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 3,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 82, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 13</span>\n      ","marker":{"lineColor":"#912767","enabled":true,"symbol":"circle"}},{"y":26.44,"date":1769904000000,"info":" <span style=\"color:#912767\" class=\"mb3 mt2 fonth8_semibold\"> Strong Sell</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 71, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 9</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Highest Price Target$60.00

Average Price Target$32.95

Lowest Price Target$16.50

The highest, average, and lowest price target of all analysts. Click on ‘Top Analysts’ to focus on the best performers.

Detailed List of Analyst Forecasts

Maria Ripps

Canaccord Genuity

$68→$30

Buy

84.05%

Upside

Reiterated

02/10/26

Analysts Are Bullish on Top Healthcare Stocks: Hims & Hers Health (HIMS), MoonLake Immunotherapeutics (MLTX)

George Hill

Deutsche Bank

$42→$31

Hold

90.18%

Upside

Reiterated

02/10/26

Hims & Hers price target lowered to $31 from $42 at Deutsche BankHims & Hers price target lowered to $31 from $42 at Deutsche Bank

Allen Lutz

Bank of America Securities

$26→$21

Sell

28.83%

Upside

Reiterated

02/09/26

Regulatory and Legal Headwinds Drive Sell Rating and Lower Price Target for Hims & Hers GLP‑1 Business

Jonna Kim

TD Cowen

$30→$20

Hold

22.70%

Upside

Reiterated

02/09/26

Regulatory Overhang on Compounded GLP‑1 Drives Hold Rating and Lowered Outlook for Hims & Hers

Daniel Grosslight

Citi

$19.33→$16.5

Sell

1.23%

Upside

Reiterated

02/09/26

Hims & Hers price target lowered to $16.50 from $30 at CitiHims & Hers price target lowered to $16.50 from $30 at Citi

Ryan MacDonald

Needham

Hold

―

Reiterated

02/09/26

Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and Hims & Hers Health (NYSE: HIMS)

David Larsen

BTIG

$60

Buy

268.10%

Upside

Reiterated

02/09/26

Prudent Pause, Strong Potential: Why Hims & Hers Remains a Buy Amid GLP‑1 Regulatory Scrutiny

Craig Hettenbach

Morgan Stanley

$40

Hold

145.40%

Upside

Reiterated

02/06/26

Balancing GLP‑1 Growth Ambitions and Heightened Legal, Regulatory, and Execution Risks: Why Hettenbach Maintains a Hold on Hims & Hers

Jailendra Singh

Truist Financial

Hold

―

Reiterated

02/06/26

Analysts Conflicted on These Healthcare Names: Encompass Health (NYSE: EHC), Hims & Hers Health (NYSE: HIMS) and Trevi Therapeutics (NASDAQ: TRVI)

Mark Mahaney

Evercore ISI

$33

Hold

102.45%

Upside

Initiated

01/12/26

Hims & Hers initiated with an In Line at Evercore ISIHims & Hers initiated with an In Line at Evercore ISI

Glen Santangelo

Barclays

$48

Buy

194.48%

Upside

Initiated

12/08/25

Hims & Hers initiated with an Overweight at BarclaysHims & Hers initiated with an Overweight at Barclays

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$30

Sell

84.05%

Upside

Reiterated

11/18/25

Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)

Justin Patterson

KeyBanc

Hold

―

Reiterated

11/04/25

KeyBanc Keeps Their Hold Rating on Hims & Hers Health (HIMS)

Michael Cherny

Leerink Partners

Hold

―

Reiterated

10/16/25

Wall Street Analysts Are Neutral on Top Healthcare Picks

Korinne Wolfmeyer

Piper Sandler

$35→$39

Hold

139.26%

Upside

Reiterated

05/06/25

Piper Sandler Remains a Hold on Hims & Hers Health (HIMS)

Analyst Type

Any

Human Analysts

Ranks

Any

Analyst Rating

Any

Upside/ Downside

Any

Action

Any

Maria Ripps

Canaccord Genuity

$68→$30

Buy

84.05%

Upside

Reiterated

02/10/26

Analysts Are Bullish on Top Healthcare Stocks: Hims & Hers Health (HIMS), MoonLake Immunotherapeutics (MLTX)

George Hill

Deutsche Bank

$42→$31

Hold

90.18%

Upside

Reiterated

02/10/26

Hims & Hers price target lowered to $31 from $42 at Deutsche BankHims & Hers price target lowered to $31 from $42 at Deutsche Bank

Allen Lutz

Bank of America Securities

$26→$21

Sell

28.83%

Upside

Reiterated

02/09/26

Regulatory and Legal Headwinds Drive Sell Rating and Lower Price Target for Hims & Hers GLP‑1 Business

Jonna Kim

TD Cowen

$30→$20

Hold

22.70%

Upside

Reiterated

02/09/26

Regulatory Overhang on Compounded GLP‑1 Drives Hold Rating and Lowered Outlook for Hims & Hers

Daniel Grosslight

Citi

$19.33→$16.5

Sell

1.23%

Upside

Reiterated

02/09/26

Hims & Hers price target lowered to $16.50 from $30 at CitiHims & Hers price target lowered to $16.50 from $30 at Citi

Ryan MacDonald

Needham

Hold

―

Reiterated

02/09/26

Analysts Offer Insights on Healthcare Companies: Immunic (NASDAQ: IMUX) and Hims & Hers Health (NYSE: HIMS)

David Larsen

BTIG

$60

Buy

268.10%

Upside

Reiterated

02/09/26

Prudent Pause, Strong Potential: Why Hims & Hers Remains a Buy Amid GLP‑1 Regulatory Scrutiny

Craig Hettenbach

Morgan Stanley

$40

Hold

145.40%

Upside

Reiterated

02/06/26

Balancing GLP‑1 Growth Ambitions and Heightened Legal, Regulatory, and Execution Risks: Why Hettenbach Maintains a Hold on Hims & Hers

Jailendra Singh

Truist Financial

Hold

―

Reiterated

02/06/26

Analysts Conflicted on These Healthcare Names: Encompass Health (NYSE: EHC), Hims & Hers Health (NYSE: HIMS) and Trevi Therapeutics (NASDAQ: TRVI)

Mark Mahaney

Evercore ISI

$33

Hold

102.45%

Upside

Initiated

01/12/26

Hims & Hers initiated with an In Line at Evercore ISIHims & Hers initiated with an In Line at Evercore ISI

Glen Santangelo

Barclays

$48

Buy

194.48%

Upside

Initiated

12/08/25

Hims & Hers initiated with an Overweight at BarclaysHims & Hers initiated with an Overweight at Barclays

Unknown Analyst

Mizuho Securities

Not Ranked

Mizuho Securities

$30

Sell

84.05%

Upside

Reiterated

11/18/25

Mizuho Securities Reaffirms Their Sell Rating on Hims & Hers Health (HIMS)

Justin Patterson

KeyBanc

Hold

―

Reiterated

11/04/25

KeyBanc Keeps Their Hold Rating on Hims & Hers Health (HIMS)

Michael Cherny

Leerink Partners

Hold

―

Reiterated

10/16/25

Wall Street Analysts Are Neutral on Top Healthcare Picks

Korinne Wolfmeyer

Piper Sandler

$35→$39

Hold

139.26%

Upside

Reiterated

05/06/25

Piper Sandler Remains a Hold on Hims & Hers Health (HIMS)

Stocks with the Highest Top Analyst Consensus in the Healthcare Sector

xxx

Find stocks in the Healthcare sector that are highly recommended by Top Performing Analysts.

Best Analysts Covering Hims & Hers Health

3 Months

xxx

Success Rate

20/27 ratings generated profit

Average Return

+7.25%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 3 Months would result in 74.07% of your transactions generating a profit, with an average return of +7.25% per trade.

1 Year

Allen LutzBank of America Securities

Success Rate

24/27 ratings generated profit

Average Return

+45.20%

reiterated a sell rating 9 days ago

Copying Allen Lutz's trades and holding each position for 1 Year would result in 88.89% of your transactions generating a profit, with an average return of +45.20% per trade.

2 Years

xxx

Success Rate

27/27 ratings generated profit

Average Return

+57.32%

reiterated a xxx

rating 9 days ago

Copying xxxxxxxxxxxxxxxxxx

trades and holding each position for 2 Years would result in 100.00% of your transactions generating a profit, with an average return of +57.32% per trade.

The Best Analyst Covering tool allows you to follow the analysts who have the best success rates and average returns on a specific stock. Only analysts that gave a Buy or Sell rating on the stock in the past 12 months are eligible for inclusion in this tool. Follow the analysts of your choice to receive real-time updates when they publish a new rating.

HIMS Analyst Recommendation Trends

Rating

Oct 25

Nov 25

Dec 25

Jan 26

Feb 26

Strong Buy

Buy

Hold

Sell

Strong Sell

total

In the current month, HIMS has received 4 Buy Ratings, 71 Hold Ratings, and 9 Sell Ratings. HIMS average Analyst price target in the past 3 months is 32.95.

Each month's total comprises the sum of three months' worth of ratings.

HIMS Financial Forecast

HIMS Earnings Forecast

Next quarter’s earnings estimate for HIMS is $0.04 with a range of -$0.04 to $0.15. The previous quarter’s EPS was $0.06. HIMS beat its EPS estimate ― of the time in the past 12 months, while its overall industry beat the EPS estimate 57.43% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Sales Forecast

Next quarter’s sales forecast for HIMS is $619.20M with a range of $608.22M to $640.15M. The previous quarter’s sales results were $598.98M. HIMS beat its sales estimates ― of the time in past 12 months, while its overall industry beat sales estimates 49.17% of the time in the same period. In the last calendar year HIMS has Performed in-line its overall industry.

HIMS Stock Forecast FAQ

What is HIMS’s average 12-month price target, according to analysts?

Based on analyst ratings, Hims & Hers Health’s 12-month average price target is 32.95.

What is HIMS’s upside potential, based on the analysts’ average price target?

Hims & Hers Health has 102.15% upside potential, based on the analysts’ average price target.

Can I see which stocks the top-ranking analysts are rating?

Yes, go to the Analysts’ Top Stocks tool to see stocks with a Strong Buy or Strong Sell analyst rating consensus, according to the top performers.

How can I follow the stock ratings of top Wall Street analysts?

Head over to our Expert Center to see a list of the top 100 Wall Street analysts and follow the analysts of your choice. Visit their profiles for more details about their stock ratings and see how they perform on a stock-by-stock basis.

Is HIMS a Buy, Sell or Hold?

Hims & Hers Health has a consensus rating of Hold which is based on 3 buy ratings, 6 hold ratings and 3 sell ratings.

What is Hims & Hers Health’s price target?

The average price target for Hims & Hers Health is 32.95. This is based on 12 Wall Streets Analysts 12-month price targets, issued in the past 3 months.
The highest analyst price target is $60.00 ,the lowest forecast is $16.50. The average price target represents 102.15% Increase from the current price of $16.3.

What do analysts say about Hims & Hers Health?

Hims & Hers Health’s analyst rating consensus is a Hold. This is based on the ratings of 12 Wall Streets Analysts.

How can I buy shares of HIMS?

Open a brokerage account, see exclusive account opening deals on our Best Online Brokers page.

Hims & Hers Health (HIMS) Stock Forecast & Price Target

HIMS Analyst Ratings

HIMS Stock 12 Month Forecast

Average Price Target

Detailed List of Analyst Forecasts​

Best Analysts Covering Hims & Hers Health

HIMS Analyst Recommendation Trends

HIMS Financial Forecast

HIMS Earnings Forecast

HIMS Sales Forecast

HIMS Stock Forecast FAQ

Detailed List of Analyst Forecasts